Do You Have Access to the Right Patients for Your Psoriatic Arthritis Therapy?

According to the American College of Rheumatology, approximately 15% of people already coping with psoriasis are further afflicted by an inflammatory condition called psoriatic arthritis.[1] In addition to the scaly rashes that characterize psoriasis, those with psoriatic arthritis develop painful inflammations in specific joints, such as the fingers and/or toes, the hands and feet, or the lower back. One rare form of psoriatic arthritis, arthritis mutilans, actually deforms and destroys the joints.

For researchers exploring therapies aimed at addressing psoriatic arthritis, numerous challenges exist. You need access to trial participants who actually have psoriatic arthritis, which is similar to rheumatoid arthritis but not exactly the same. You need access to clinicians that are adept at working with patients with psoriatic arthritis and to sites with experience treating immune-mediated inflammatory disorders (IMID).

In short, you need a CRO partner with the reach and experience to help you set up and manage successful clinical trials. That’s where Worldwide Clinical Trials comes in. With more than 30 years of experience supporting IMID research, Worldwide is an internationally acclaimed expert in clinical trial management. We offer full-service Phase I-Phase IV and real-world evidence clinical research services for studies in psoriatic arthritis and other immune-mediated inflammatory disorders. All of Worldwide’s completed IMID studies have met recruitment timelines, and our geographic reach extends across more than 60 countries, ensuring you have access to a vast biologic-treatment-naive patient population.

[1] https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis